FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590019071> ?p ?o ?g. }

• W2590019071 endingPage "8051" @default.
• W2590019071 startingPage "8051" @default.
• W2590019071 abstract "8051 Background: Steatohepatits, otherwise known as fatty liver, has been associated with a number of chemotherapy agents, in particular the fluoropyrimidines. Chemotherapy Associated Steatohepatitis (CASH) can cause a number of clinical problems including misinterpretation of fatty liver for tumor progression and increased morbidity and mortality post liver resection (Kooby et al J Gastrointest Surg 2003). There has been no formal evaluation of the relative incidence of CASH with modern chemotherapy agents although a recent report suggests that oxaliplatin may be associated with hepatic sinusoidal obstruction (Rubbia-Brandt et al Ann Oncol 2004). Methods: We randomly identified 75 chemonaive patients from our institution that were treated with at least 2 months of either 5-fluorouracil and leucovorin (FU/LV) (n=25), irinotecan + FU/LV (n=25), or oxaliplatin + FU/LV (n=25) for advanced colorectal carcinoma (CRC). A quantitative assessment of CASH was performed by measuring Hounsfield units in 3 separate areas on the liver, spleen and paraspinal muscles respectively on pre and post chemotherapy computed tomography (CT) scans in each patient. Results: Attenuation measurements were performed on all 75 patients at a number of levels in the right lobe of the liver and at the closest corresponding levels of the spleen and muscle, immediately prior to and after administration of chemotherapy. Mean liver-spleen attenuation difference values were compared and those values which reduced by more than a predefined threshold value post chemotherapy were considered fatty. The results show 6 of 25 (24%) of the 5FU group, 12 of 25 (48%) of the CPT11 group, and 7 of 25 (28%) of the FOLFOX treated group showed attenuation differences consistent with interval development of diffuse fatty change in the liver. Conclusions: CASH can occur with modern chemotherapy agents. Verification of these results are necessary using more accurate measures of steatohepatitis such as non-contrast CT scans. With the increasing utilization of these agents for neoadjuvant therapy for advanced CRC, clinicopatholoigical studies are required to further characterize CASH and its potential complications. No significant financial relationships to disclose." @default.
• W2590019071 created "2017-03-03" @default.
• W2590019071 creator A5005824918 @default.
• W2590019071 creator A5013690480 @default.
• W2590019071 creator A5058825770 @default.
• W2590019071 creator A5069644669 @default.
• W2590019071 creator A5090169126 @default.
• W2590019071 date "2005-06-01" @default.
• W2590019071 modified "2023-09-27" @default.
• W2590019071 title "A comparative assessment of the incidence of steatohepatitis seen with modern chemotherapy agents" @default.
• W2590019071 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.8051" @default.
• W2590019071 hasPublicationYear "2005" @default.
• W2590019071 type Work @default.
• W2590019071 sameAs 2590019071 @default.
• W2590019071 citedByCount "0" @default.
• W2590019071 crossrefType "journal-article" @default.
• W2590019071 hasAuthorship W2590019071A5005824918 @default.
• W2590019071 hasAuthorship W2590019071A5013690480 @default.
• W2590019071 hasAuthorship W2590019071A5058825770 @default.
• W2590019071 hasAuthorship W2590019071A5069644669 @default.
• W2590019071 hasAuthorship W2590019071A5090169126 @default.
• W2590019071 hasConcept C121608353 @default.
• W2590019071 hasConcept C126322002 @default.
• W2590019071 hasConcept C126838900 @default.
• W2590019071 hasConcept C2776694085 @default.
• W2590019071 hasConcept C2778772119 @default.
• W2590019071 hasConcept C2779134260 @default.
• W2590019071 hasConcept C2779478299 @default.
• W2590019071 hasConcept C2780259306 @default.
• W2590019071 hasConcept C2780962732 @default.
• W2590019071 hasConcept C526805850 @default.
• W2590019071 hasConcept C71924100 @default.
• W2590019071 hasConcept C90924648 @default.
• W2590019071 hasConceptScore W2590019071C121608353 @default.
• W2590019071 hasConceptScore W2590019071C126322002 @default.
• W2590019071 hasConceptScore W2590019071C126838900 @default.
• W2590019071 hasConceptScore W2590019071C2776694085 @default.
• W2590019071 hasConceptScore W2590019071C2778772119 @default.
• W2590019071 hasConceptScore W2590019071C2779134260 @default.
• W2590019071 hasConceptScore W2590019071C2779478299 @default.
• W2590019071 hasConceptScore W2590019071C2780259306 @default.
• W2590019071 hasConceptScore W2590019071C2780962732 @default.
• W2590019071 hasConceptScore W2590019071C526805850 @default.
• W2590019071 hasConceptScore W2590019071C71924100 @default.
• W2590019071 hasConceptScore W2590019071C90924648 @default.
• W2590019071 hasIssue "16_suppl" @default.
• W2590019071 hasLocation W25900190711 @default.
• W2590019071 hasOpenAccess W2590019071 @default.
• W2590019071 hasPrimaryLocation W25900190711 @default.
• W2590019071 hasRelatedWork W102477170 @default.
• W2590019071 hasRelatedWork W1952215728 @default.
• W2590019071 hasRelatedWork W1965756961 @default.
• W2590019071 hasRelatedWork W1973533688 @default.
• W2590019071 hasRelatedWork W2037724349 @default.
• W2590019071 hasRelatedWork W2069660570 @default.
• W2590019071 hasRelatedWork W2417591555 @default.
• W2590019071 hasRelatedWork W2545945608 @default.
• W2590019071 hasRelatedWork W2593789845 @default.
• W2590019071 hasRelatedWork W3129030645 @default.
• W2590019071 hasVolume "23" @default.
• W2590019071 isParatext "false" @default.
• W2590019071 isRetracted "false" @default.
• W2590019071 magId "2590019071" @default.
• W2590019071 workType "article" @default.